Abstract
Corneal angiogenesis and lymphangiogenesis are induced by vascular endothelial growth factors (VEGFs) signaling through its receptors VEGFR-1, -2, and -3. Endostatin is a peptide antagonist of these receptors that causes inhibition of bFGF-induced corneal angiogenesis and lymphangiogenesis. Here we show that binding of VEGF-C and endostatin to recombinant VEGFR-3 is competitive. Alignments of the primary amino acid sequences of VEGF-C and the C-terminal endostatin peptide (mEP: LEQKAASCHNSYIVLCIENSFMTSFSK) identified two conserved cysteine residues separated by seven amino acids. Peptides of VEGF-C and mEP containing these conserved residues bound toVEGFR-3. However, substitution of alanine for either of the cysteines in the mEP peptide perturbed the secondary structure, and this mutated peptide was unable to bind to VEGFR-3. Analysis by surface plasmon resonance demonstrated that the binding of the mEP peptide for recombinant VEGFR-3 had a Ka of 1.41x107M-1s-1, Kd of 0.6718 s-1, and a KD of 4.78x10-8M. Characterization of the mechanism of endostatin binding to VEGFR-3 may lead to the development of novel therapies for lymphangiogenesis-related disorders, such as transplant rejection, lymphedema, and cancer metastasis.
Keywords: Endostatin, lymphangiogenesis, peptide fragment, surface plasmon resonance, VEGF, VEGFR
Protein & Peptide Letters
Title:Characterization of the Interaction Between Endostatin Short Peptide and VEGF Receptor 3
Volume: 19 Issue: 9
Author(s): Kyu-Yeon Han, Dimitri T. Azar, Abdellah Sabri, Hyun Lee, Sandeep Jain, Bao-Shiang Lee and Jin-Hong Chang
Affiliation:
Keywords: Endostatin, lymphangiogenesis, peptide fragment, surface plasmon resonance, VEGF, VEGFR
Abstract: Corneal angiogenesis and lymphangiogenesis are induced by vascular endothelial growth factors (VEGFs) signaling through its receptors VEGFR-1, -2, and -3. Endostatin is a peptide antagonist of these receptors that causes inhibition of bFGF-induced corneal angiogenesis and lymphangiogenesis. Here we show that binding of VEGF-C and endostatin to recombinant VEGFR-3 is competitive. Alignments of the primary amino acid sequences of VEGF-C and the C-terminal endostatin peptide (mEP: LEQKAASCHNSYIVLCIENSFMTSFSK) identified two conserved cysteine residues separated by seven amino acids. Peptides of VEGF-C and mEP containing these conserved residues bound toVEGFR-3. However, substitution of alanine for either of the cysteines in the mEP peptide perturbed the secondary structure, and this mutated peptide was unable to bind to VEGFR-3. Analysis by surface plasmon resonance demonstrated that the binding of the mEP peptide for recombinant VEGFR-3 had a Ka of 1.41x107M-1s-1, Kd of 0.6718 s-1, and a KD of 4.78x10-8M. Characterization of the mechanism of endostatin binding to VEGFR-3 may lead to the development of novel therapies for lymphangiogenesis-related disorders, such as transplant rejection, lymphedema, and cancer metastasis.
Export Options
About this article
Cite this article as:
Han Kyu-Yeon, T. Azar Dimitri, Sabri Abdellah, Lee Hyun, Jain Sandeep, Lee Bao-Shiang and Chang Jin-Hong, Characterization of the Interaction Between Endostatin Short Peptide and VEGF Receptor 3, Protein & Peptide Letters 2012; 19 (9) . https://dx.doi.org/10.2174/092986612802084465
DOI https://dx.doi.org/10.2174/092986612802084465 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Organogels: “GelVolution” in Topical Drug Delivery - Present and Beyond
Current Pharmaceutical Design AAV-Mediated Gene Supply for Treatment of Degenerative and Neovascular Retinal Diseases
Current Gene Therapy Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Antecedents of Voluntary Surgical Sterilization Among Poor Women in Tamil Nadu: Urban vs. Rural Areas
Current Women`s Health Reviews Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Photoprotective Carotenoids Lutein and Zeaxanthin: Their Role in AMD
Current Nutrition & Food Science Polyene Macrolide Antibiotic Biosynthesis
Current Medicinal Chemistry Knee Osteoarthritis and Exercise Adherence: A Review
Current Aging Science Cytotoxicity, Antioxidant and Apoptosis Studies of Quercetin-3-O Glucoside and 4-(β-D-Glucopyranosyl-1→4-α-L-Rhamnopyranosyloxy)-Benzyl Isothiocyanate from Moringa oleifera
Anti-Cancer Agents in Medicinal Chemistry Use of Human Umbilical Cord Blood (HUCB) Cells to Repair the Damaged Brain
Current Neurovascular Research Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Practical Considerations for Omics Experiments in Biomedical Sciences
Current Pharmaceutical Biotechnology The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology